Vktx presentation to shareholders
Vktx presentation to shareholders
Vktx presentation to shareholders
@financepresentations1 month ago
- â Developing novel therapeutics for metabolic and endocrine diseases
- á Multiple clinical programs demonstrate best-in-class efficacy data
- á VK2735: GLP-1/GIP dual agonist for obesity
- ⪠VENTURE Phase 2 obesity study successfully achieved primary, secondary endpoints
- á VK2735 Oral: GLP-1/GIP dual agonist for obesity
- ⪠Phase 1 study demonstrated positive PoC, reduced in body weight; Phase 2 planned for 4Q24
- á VK2809: Selective thyroid receptorβ agonist for NASH/MASH
- ⪠VOYAGE Phase 2b trial successfully demonstrated NASH resolution, fibrosis improvement
- á VK0214: Selective thyroid receptorβ agonist for X-ALD
- ⪠Phase 1b in patients ongoing; data expected 2H24
- á VK2735 Oral: Additional Phase 1 data in healthy subjects
- á VK0214: Phase 1b data in X-linked adrenoleukodystrophy
Forward-Looking Statements
This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfully research, obtain regulatory approvals fo r, develop and commercialize products based upon our technologies; our ability to obtain and maintain proprietary protection for our technologies and product candidates; our reliance on third parties to manufacture our preclinical and clinical drug supplies; competitive pressures; our ability to obtain and maintain strategic collaborations; compliance with our in-license agreements; our ability to successfully execute on, and receive favorable results from, our proprietary drug development efforts; market acceptance of our drug candidates; retaining members of our senior management; and our ability to raise additional funds to finance our operations.
The forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.
For more information regarding risks and uncertainties that could affect the results of our operations or financial condition review our filings with the Securities and Exchange Commission (in particular, our most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q).
Investment Highlights
â Metabolic Disease Programs
â Rare Disease Program
Pipeline Overview
Potential data events expected over next 3-6 months
4
VK2735: Dual GLP-1/GIP Receptor Agonist
Metabolic Disorders